October 17, 2012 Novel Zfp Therapeutic Approach Selectively Represses Only the Disease-Causing Gene RICHMOND, Calif., Oct. 17, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its program with Shire AG (LSE: SHP, NASDAQ: SHPG) to develop a novel ZFP Therapeutic approach to Huntington's disease (HD), an inherited progressive neurodegenerative disease
This post first appeared on Enfermedad De Huntington, Noticias, Avances, Trata, please read the originial post: here
